Zydus receives tentative approval from the USFDA for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets

Zydus receives tentative approval from the USFDA for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets ______________________________________________________________ Ahmedabad, 14 March 2019 Zydus Cadila has received the tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride Extended- Release Tablets, (US RLD – JANUMET® XR), 50 mg/500 mg, 50 mg/1,000 mg and 100 mg/1,000 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. It contains two oral antidiabetic medications used in the management of type 2 diabetes - sitagliptin and metformin hydrochloride extended-release. The group now has 255 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗